[Triple-negative breast cancer therapy via nectin-4 targeting].

about

[Triple-negative breast cancer therapy via nectin-4 targeting].

Item

http://www.wikidata.org/entity/Q50098119

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

[Triple-negative breast cancer therapy via nectin-4 targeting].

@en

[Triple-negative breast cancer therapy via nectin-4 targeting].

@nl

type

Item

label

[Triple-negative breast cancer therapy via nectin-4 targeting].

@en

[Triple-negative breast cancer therapy via nectin-4 targeting].

@nl

prefLabel

[Triple-negative breast cancer therapy via nectin-4 targeting].

@en

[Triple-negative breast cancer therapy via nectin-4 targeting].

@nl

P1476

[Triple-negative breast cancer therapy via nectin-4 targeting].

@en

P2093

Daniel Birnbaum

http://www.w3.org/2001/XMLSchema#string

François Bertucci

http://www.w3.org/2001/XMLSchema#string

Manel M-Rabet

http://www.w3.org/2001/XMLSchema#string

Marc Lopez

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Mutations in PVRL4, encoding cell adhesion molecule nectin-4, cause ectodermal dysplasia-syndactyly syndrome.

Basal breast cancer: a complex and deadly molecular subtype

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.

Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation.

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

[Nectin and nectin-like molecules as markers, actors and targets in cancer].

P304

936-939

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1051/MEDSCI/20173311007

http://www.w3.org/2001/XMLSchema#string

P407

Af-Faransiis

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29200388

http://www.w3.org/2001/XMLSchema#string